Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245539 · ClinicalTrials.gov registry record · Phase 1
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
A Phase 1 study of Schizophrenia and Blood Pressure, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 10
- Study locations
NCT05245539: Completed Phase 1 study of Schizophrenia and Blood Pressure, sponsored by Cerevel Therapeutics.
NCT05245539 is a Phase 1 study of Schizophrenia and Blood Pressure that has completed, run by Cerevel Therapeutics. The registered enrollment target is 151 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (31% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05245539, a Phase 1 study of Schizophrenia and Blood Pressure, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.
Conditions Studied
Interventions
- DRUG CVL-231
Study Locations (10)
Arkansas
- Pillar Clinical Research LLC - Bentonville
- Woodland International Research Group LLC - ERG - PPDS - Little Rock
Illinois
- Uptown Research Institute LLC - Chicago
- Pillar Clinical Research LLC - Lincolnwood
Texas
- Community Clinical Research - Austin
- Pillar Clinical Research LLC - Richardson
California
- Collaborative NeuroScience Research, LLC - Torrance - Apex - PPDS - Long Beach
Florida
- Innovative Clinical Research, Inc - ClinEdge - PPDS - Miami
New Jersey
- Hassman Research Institute - Apex - PPDS - Marlton
Ohio
- Neuro-Behavioral Clinical Research, Inc. - North Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2022-11-14 |
| Phase | Phase 1 |
What the finished NCT05245539 record still lists
NCT05245539 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (31% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which CVL-231 is the first listed.
NCT05245539 lists 10 locations in 7 states (Arkansas, Illinois, Texas).
Frequently Asked Questions
What is clinical trial NCT05245539 about?
NCT05245539 is a clinical study titled "Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia". The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.
What is the current status of trial NCT05245539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2022-01-24. Estimated completion is 2022-11-14.
What conditions does trial NCT05245539 study?
This clinical trial studies the following conditions: Schizophrenia, Blood Pressure.
What interventions are being tested in trial NCT05245539?
The interventions under investigation include: CVL-231 (DRUG).
Who is sponsoring clinical trial NCT05245539?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245539 being conducted?
This trial has 10 study locations across Arkansas, California, Florida, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05245539's enrollment target sits among peer trials
151 106th of 315 higher than 210 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI